AU2013266145A1 - Diabetes biomarkers - Google Patents

Diabetes biomarkers Download PDF

Info

Publication number
AU2013266145A1
AU2013266145A1 AU2013266145A AU2013266145A AU2013266145A1 AU 2013266145 A1 AU2013266145 A1 AU 2013266145A1 AU 2013266145 A AU2013266145 A AU 2013266145A AU 2013266145 A AU2013266145 A AU 2013266145A AU 2013266145 A1 AU2013266145 A1 AU 2013266145A1
Authority
AU
Australia
Prior art keywords
cell
central memory
sample
level
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013266145A
Other languages
English (en)
Inventor
Tihamer Orban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orban Biotech LLC
Original Assignee
Orban Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech LLC filed Critical Orban Biotech LLC
Publication of AU2013266145A1 publication Critical patent/AU2013266145A1/en
Priority to AU2019200824A priority Critical patent/AU2019200824B2/en
Priority to AU2021202609A priority patent/AU2021202609A1/en
Priority to AU2023222980A priority patent/AU2023222980A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Ecology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013266145A 2012-05-24 2013-05-24 Diabetes biomarkers Abandoned AU2013266145A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019200824A AU2019200824B2 (en) 2012-05-24 2019-02-07 Diabetes biomarkers
AU2021202609A AU2021202609A1 (en) 2012-05-24 2021-04-28 Diabetes biomarkers
AU2023222980A AU2023222980A1 (en) 2012-05-24 2023-08-31 Diabetes biomarkers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
US61/651,144 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200824A Division AU2019200824B2 (en) 2012-05-24 2019-02-07 Diabetes biomarkers

Publications (1)

Publication Number Publication Date
AU2013266145A1 true AU2013266145A1 (en) 2015-01-15

Family

ID=49621783

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013266145A Abandoned AU2013266145A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers
AU2019200824A Ceased AU2019200824B2 (en) 2012-05-24 2019-02-07 Diabetes biomarkers
AU2021202609A Abandoned AU2021202609A1 (en) 2012-05-24 2021-04-28 Diabetes biomarkers
AU2023222980A Pending AU2023222980A1 (en) 2012-05-24 2023-08-31 Diabetes biomarkers

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019200824A Ceased AU2019200824B2 (en) 2012-05-24 2019-02-07 Diabetes biomarkers
AU2021202609A Abandoned AU2021202609A1 (en) 2012-05-24 2021-04-28 Diabetes biomarkers
AU2023222980A Pending AU2023222980A1 (en) 2012-05-24 2023-08-31 Diabetes biomarkers

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP3767295A1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN107003315B (zh) * 2014-12-25 2018-09-25 株式会社日立制作所 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
WO2021260654A1 (en) 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
EP4373517A1 (en) 2021-06-17 2024-05-29 Phaim Pharma Ltd Individualized cell therapy using patient-derived antigen-specific regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930415A4 (en) * 2005-09-30 2009-05-13 Univ Kyoto DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC
US9176122B2 (en) * 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers

Also Published As

Publication number Publication date
WO2013177505A1 (en) 2013-11-28
AU2023222980A1 (en) 2023-09-21
KR102172285B1 (ko) 2020-11-02
MX357169B (es) 2018-06-28
IN2014DN10259A (enExample) 2015-08-07
US20190137483A1 (en) 2019-05-09
ZA201409006B (en) 2016-07-27
ES2810227T3 (es) 2021-03-08
JP2021001899A (ja) 2021-01-07
JP6761827B2 (ja) 2020-09-30
JP6312332B2 (ja) 2018-04-18
US20250237643A1 (en) 2025-07-24
AU2021202609A1 (en) 2021-05-27
US20160299128A1 (en) 2016-10-13
JP2023011814A (ja) 2023-01-24
AU2019200824B2 (en) 2021-06-24
AU2019200824A1 (en) 2019-04-04
EP2856149A4 (en) 2016-06-01
DK2856149T3 (da) 2020-08-17
JP2015520378A (ja) 2015-07-16
JP2024150702A (ja) 2024-10-23
KR20150022878A (ko) 2015-03-04
EP3767295A1 (en) 2021-01-20
US20130316375A1 (en) 2013-11-28
EP2856149A1 (en) 2015-04-08
JP2018116061A (ja) 2018-07-26
US20230333094A1 (en) 2023-10-19
CN104520707B (zh) 2018-03-27
MX2014014348A (es) 2015-06-05
CA2874507A1 (en) 2013-11-28
CN104520707A (zh) 2015-04-15
EP2856149B1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
US20250237643A1 (en) Diabetes Biomarkers
Couper et al. ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.
Herold et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals
Litherland et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus
WO1993001838A1 (en) Method for identifying t cells disease involved in autoimmune disease
US10914743B2 (en) Kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases
Aamodt et al. The pathophysiology, presentation and classification of Type 1 diabetes
US11602556B2 (en) Insulin mimotopes and methods of using the same
Bollyky et al. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
Tizazu et al. Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy
Xiang et al. Expression of Th17 and C [D. sup. 4+] C [D. sup. 25+] T regulatory cells in peripheral blood of acute leukemia patients and their prognostic significance
Burlingham et al. Delayed type hypersensitivity responses
Almeida Glycans as novel immunomodulators in Idiopathic Inflammatory Myopathies
Hill Immunomodulatory responses in the pancreas in health and disease
Piya et al. Understanding the Immunology of Type 1 Diabetes—An Overview of Current Knowledge and Perspectives for the Future
Ragogna Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes
Boubacar et al. Myasthenia Gravis Associated with Diabetes about an Observation in Dakar, Senegal (West Africa) and Review of the Literature
Franzese et al. T1D PROGRESSION IS ASSOCIATED WITH LOSS OF CD3+ CD56+ REGULATORY CELLS

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted